View Older Stories View More Recent Stories

Nov 18, 2021 09:00AM New Data Show Dramatic Emotional Toll of Pandemic on Unpaid Caregivers of People Living With Cancer, Affecting Mental Health and Relationships
Nov 18, 2021 06:46AM Merck's (MRK) KEYTRUDA Granted FDA Approval as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following Surgery
Nov 18, 2021 06:45AM FDA Approves Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following Surgery
Nov 17, 2021 06:46AM Merck (MRK) Announces Expiration of Hart-Scott-Rodino Act Waiting Period and Extension of Tender Offer to Acquire Acceleron Pharma (XLRN)
Nov 17, 2021 06:45AM Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period and Extension of Tender Offer to Acquire Acceleron Pharma Inc.
Nov 17, 2021 06:01AM Merck (MRK) and Ridgeback to Report Phase 3 Data for Molnupiravir
Nov 17, 2021 06:00AM Merck and Ridgeback to Present Phase 3 Data for Molnupiravir, an Investigational Oral COVID-19 Antiviral Medicine, at American Society of Tropical Medicine and Hygiene (ASTMH) 2021 Annual Meeting
Nov 17, 2021 01:05AM Imugene Announces Clinical Trial Supply Agreement with Merck KGaA, Darmstadt, Germany and Pfizer to Evaluate HER-Vaxx in Combination with Avelumab for Treatment of Gastric Cancer
Nov 11, 2021 06:45AM Merck Announces Initiation of Phase 3 Study Evaluating VERQUVO® (vericiguat) in Patients with Chronic Heart Failure and Reduced Ejection Fraction Who Have Not Had a Recent Worsening Heart Failure Eve
Nov 10, 2021 05:05PM IMV Inc. Announces Third Quarter 2021 Financial and Operational Update
Nov 10, 2021 08:05AM Merck (MRK), Ridgeback Announce Japanese Government to Purchase 1.6 Million Courses of Molnupiravir, an Investigational Oral COVID-19 Antiviral Medicine, Upon Authorization or Approval
Nov 10, 2021 08:00AM Merck and Ridgeback Announce Japanese Government to Purchase 1.6 Million Courses of Molnupiravir, an Investigational Oral COVID-19 Antiviral Medicine, Upon Authorization or Approval
Nov 9, 2021 06:04AM Merck (MRK) and Ridgeback Announce Additional Purchase of 1.4M Courses of Molnupiravir by the US Government
Nov 9, 2021 06:00AM Merck and Ridgeback Announce U.S. Government to Purchase 1.4 Million Additional Courses of Molnupiravir, an Investigational Oral Antiviral Medicine, for the Treatment of Mild-to-Moderate COVID-19 in A
Nov 8, 2021 04:32PM Merck (MRK) Acquisition of Acceleron Pharma Cleared by Antitrust Authorities in Germany and Austria
Nov 8, 2021 04:30PM Merck Announces Receipt of Antitrust Clearance in Germany and Austria Relating to Tender Offer to Acquire Acceleron Pharma Inc.
Nov 4, 2021 06:46AM Merck's (MRK) Molnupiravir Approved in the UK
Nov 4, 2021 06:40AM Merck and Ridgeback’s Molnupiravir, an Oral COVID-19 Antiviral Medicine, Receives First Authorization in the World
Oct 31, 2021 01:35PM New Research for KEYTRUDA® (pembrolizumab) at Society for Melanoma Research (SMR) 2021 Congress Reinforces Merck’s Commitment to Patients With Melanoma Across Stages of Disease
Oct 29, 2021 04:34PM Merck Announces Withdrawal and Refiling under the Hart-Scott-Rodino Act and Extension of Tender Offer to Acquire Acceleron Pharma Inc.
Oct 28, 2021 09:00AM MilliporeSigma Announces New Innovation & Capacity to Advance Next Generation Antibody-drug Conjugate (ADC) Therapies
Oct 28, 2021 06:30AM Merck Announces Third-Quarter 2021 Financial Results
Oct 27, 2021 06:45AM Merck (MRK) Reports New Data from Phase 2b Clinical Trial Evaluating Efficacy and Safety of Islatravir in Combination With Doravirine
Oct 27, 2021 06:45AM Merck Presents New Data from Ongoing Phase 2b Clinical Trial Evaluating Efficacy and Safety of Investigational Islatravir in Combination With Doravirine Through 144 Weeks for HIV-1 Treatment at EACS 2
Oct 27, 2021 06:00AM Merck (MRK) Announces License Agreement with The Medicines Patent Pool for Molnipiravir
Oct 27, 2021 06:00AM The Medicines Patent Pool (MPP) and Merck Enter Into License Agreement for Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine, to Increase Broad Access in Low- and Middle-Income Countri
Oct 26, 2021 06:47AM Gilead (GILD), Merck (MRK) Initiate Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Lenacapavir and Investigational Islatravir for HIV-1 Treatment in Virologically Suppr
Oct 26, 2021 06:45AM Gilead and Merck Initiate Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Lenacapavir and Investigational Islatravir for HIV-1 Treatment in Virologically Suppressed Adul
Oct 25, 2021 06:46AM Merck (MRK) Reports Positive Top-Line Results from Pivotal Phase 3 Trials Evaluating Combination of Doravirine/Islatravir for the Treatment of People with HIV-1 Infection
Oct 25, 2021 06:45AM Merck Announces Positive Top-Line Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily Oral Fixed Dose Combination of Doravirine/Islatravir for the Treatment of People with HIV-1
Oct 25, 2021 06:02AM Merck (MRK) And Ridgeback Announce Initiation of a Rolling Review by EU Agency for Molnupiravir,
Oct 25, 2021 06:00AM Merck and Ridgeback Announce Initiation of a Rolling Review by the European Medicines Agency for Molnupiravir, an Investigational Oral Antiviral Medicine, for the Treatment of COVID-19 in Adults
Oct 22, 2021 06:46AM Merck (MRK) Announces European Commission Approves KEYTRUDA Plus Chemotherapy as Treatment for Certain Patients With Locally Recurrent Unresectable or Metastatic TNBC
Oct 22, 2021 06:45AM European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Treatment for Certain Patients With Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer (T
Oct 21, 2021 05:43AM CDC ACIP Unanimously Votes to Recommends Merck's (MRK) VAXNEUVANCE in Series with PNEUMOVAX as Option for Pneumococcal Vaccination in Appropriate Adults
Oct 20, 2021 07:07PM CDC ACIP Unanimously Votes to Provisionally Recommend Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) in Series with PNEUMOVAX ® 23 (Pneumococcal Vaccine Polyvalent) as an Option
Oct 20, 2021 05:42AM Merck (MRK) Announces Voluntary Nationwide Recall of CUBICIN 500mg, Due to Presence of Particulate Matter Identified as Glass Particles
Oct 19, 2021 07:30PM Merck Issues Voluntary Nationwide Recall of CUBICIN® (daptomycin for injection) 500 mg, Lot 934778, Due to Presence of Particulate Matter Identified as Glass Particles
Oct 15, 2021 07:20AM Merck (MRK), Eisai Receive Positive EU CHMP Opinions for KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) in Two Different Types of Cancer
Oct 15, 2021 07:20AM Merck and Eisai Receive Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Two Different Types of Cancer
Oct 15, 2021 07:15AM Merck (MRK) Announces Positive CHMP Opinion for VAXNEUVANCE (Pneumococcal 15-valent Conjugate Vaccine) in Individuals 18 Years of Age and Older
Oct 15, 2021 07:15AM Merck Receives Positive CHMP Opinion for VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) in Individuals 18 Years of Age and Older
Oct 13, 2021 02:46PM Merck (MRK) Announces FDA Approves KEYTRUDA Plus Chemotherapy, With or Without Bevacizumab, as Treatment for Patients With Persistent, Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L
Oct 13, 2021 02:45PM FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Bevacizumab, as Treatment for Patients With Persistent, Recurrent or Metastatic Cervical Cancer Whose Tumors Expres
Oct 12, 2021 09:00AM MilliporeSigma Announces Completion of New Viral Vector Contract Development Manufacturing Facility for Gene Therapy
Oct 12, 2021 06:51AM UPDATE: Merck (MRK) Commences Cash Tender Offer to Acquire Acceleron Pharma (XLRN) for $180/sh, Deal Announced on Sept. 30
Oct 12, 2021 06:45AM Merck Begins Tender Offer to Acquire Acceleron Pharma Inc.
Oct 11, 2021 06:00AM Merck (MRK) and Ridgeback Submit Emergency Use Authorization Application to the U.S. FDA for Molnupiravir
Oct 11, 2021 06:00AM Merck and Ridgeback Announce Submission of Emergency Use Authorization Application to the U.S. FDA for Molnupiravir, an Investigational Oral Antiviral Medicine, for the Treatment of Mild-to-Moderate C
Oct 5, 2021 08:30AM  Merck and Emmy-Nominated Actress Yvonne Orji Unveil Uncovering TNBC, Highlighting the Challenges Faced by Black Women Diagnosed with Triple-Negative Breast Cancer
View More Recent Stories View Older Stories